Sign in

TECH on Nasdaq

Bio-Techne

American life sciences company

Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.3 Wikipedia text CC BY-SA 4.0

$72.53 up 0.03 (0.03%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 21, 2026.

Overview

$1.2BRevenue, fiscal 20266
$181.9MNet income, fiscal 20266
1976Founded1

Compare with Novavax, Halozyme Therapeutics or BioCryst Pharmaceuticals, or pick any stock.

  • TickerTECH on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersMinneapolis1
  • Websitewww.bio-techne.com
  • Incorporated inMN7
  • Business address614 Mckinley Place Ne, Minneapolis, Mn7
  • Filer categoryLarge accelerated filer7
  • Legal formBusiness Corporation4
  • LEI54930073RLKQ51TILZ354
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered address614 McKinley PL NE, 55413 Minneapolis, United States4
  • Registered withOffice of the Minnesota Secretary of State Business & Lien system, 3X-10744

See how the biggest companies compare on our leaderboards

Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

65.8%Gross margin6
20.7%Operating margin6
15.0%Net margin6
-0.4%Revenue growth, 20266
8.6%Return on equity6
$263.2MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue34¢$416.0M
  • Selling, general and admin37¢$452.4M
  • Other costs9¢$106.0M
  • Income tax5¢$58.8M
  • Profit15¢$181.9M

Out of $1.2B in revenue.6

Where each dollar of operating cash went, fiscal 2026

  • Capital spending10¢$28.9M
  • Dividends paid17¢$49.9M
  • Share buybacks14¢$41.7M
  • Kept or used elsewhere59¢$171.6M

Out of $292.1M of cash from operations.6

Financial statements

Revenue10111213146$1.2B in 2026+70% since 2019
0$500.0M$1.0B$1.5B2019: $714.0M$714.0M20192020: $738.7M$738.7M2020+3%2021: $931.0M$931.0M2021+26%2022: $1.1B$1.1B2022+19%2023: $1.1B$1.1B2023+3%2024: $1.2B$1.2B2024+2%2025: $1.2B$1.2B2025+5%2026: $1.2B$1.2B2026−0%
Gross profit10111213146$799.1M in 2026+69% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $473.5M$473.5M20192020: $483.2M$483.2M2020+2%2021: $632.9M$632.9M2021+31%2022: $756.5M$756.5M2022+20%2023: $769.8M$769.8M2023+2%2024: $769.7M$769.7M2024−0%2025: $790.3M$790.3M2025+3%2026: $799.1M$799.1M2026+1%
Operating income10111213146$251.9M in 2026+72% since 2019
0$100.0M$200.0M$300.0M2019: $146.7M$146.7M20192020: $157.4M$157.4M2020+7%2021: $237.3M$237.3M2021+51%2022: $296.6M$296.6M2022+25%2023: $298.9M$298.9M2023+1%2024: $206.7M$206.7M2024−31%2025: $102.3M$102.3M2025−51%2026: $251.9M$251.9M2026+146%
Net income10111213146$181.9M in 2026+89% since 2019
0$100.0M$200.0M$300.0M2019: $96.1M$96.1M20192020: $229.3M$229.3M2020+139%2021: $140.4M$140.4M2021−39%2022: $272.1M$272.1M2022+94%2023: $285.3M$285.3M2023+5%2024: $168.1M$168.1M2024−41%2025: $73.4M$73.4M2025−56%2026: $181.9M$181.9M2026+148%
Fiscal year20192020202120222023202420252026
Revenue$714.0M10$738.7M11$931.0M12$1.1B13$1.1B14$1.2B6$1.2B6$1.2B6
Cost of revenue$240.5M10$255.5M11$298.2M12$349.1M13$366.9M14$389.3M6$429.4M6$416.0M6
Gross profit$473.5M10$483.2M11$632.9M12$756.5M13$769.8M14$769.7M6$790.3M6$799.1M6
Selling, general and admin$264.4M10$260.6M11$325.0M12$372.8M13$378.4M14$466.4M6$588.5M6$452.4M6
Operating expenses$459.9M13$470.9M14$563.0M6$688.0M6$547.2M6
Operating income$146.7M10$157.4M11$237.3M12$296.6M13$298.9M14$206.7M6$102.3M6$251.9M6
Interest$21.7M10$19.2M11$14.0M12$11.3M12$11.2M12
Income before tax$301.4M13$338.7M14$185.7M6$98.5M6$240.7M6
Income tax$15.9M10$47.2M11$8.6M12$38.3M13$53.2M14$17.6M6$25.1M6$58.8M6
Net income$96.1M10$229.3M11$140.4M12$272.1M13$285.3M14$168.1M14$73.4M14$181.9M6
Earnings per share$2.5410$6.0011$0.9112$1.7313$1.8114$1.076$0.476$1.176
Earnings per share (diluted)$2.4710$5.8211$0.8712$1.6613$1.7614$1.056$0.466$1.166
Shares (weighted, basic)156.9M shares13157.2M shares14157.7M shares6157.5M shares6156.0M shares6
Shares (weighted, diluted)164.1M shares13161.9M shares14160.8M shares6159.7M shares6157.0M shares6

Compare Bio-Techne with another company

Corporate structure

Bio-Techne sits at the top of its group. 10 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Bio-Techne

  • FMR LLC Filed SCHEDULE 13G/A on Bio-Techne, latest Aug 6, 2026 (2 filings since May 6, 2026)
  • VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Bio-Techne, latest Apr 29, 2026
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Bio-Techne, latest Mar 26, 2026 (4 filings since Feb 9, 2022)
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SCHEDULE 13G/A on Bio-Techne, latest Nov 14, 2025 (4 filings since Nov 14, 2024)
  • BlackRock Filed SCHEDULE 13G/A on Bio-Techne, latest Jul 16, 2025 (8 filings since Jan 25, 2022)
  • Bio-Techne Minneapolis, Minnesota, United States
    • ProteinSimple (United States) Subsidiary · Santa Clara, California, United States
    • Advanced Cell Diagnostics, Inc. Subsidiary · California, United States
    • Asuragen, Inc. Subsidiary · Delaware, United States
    • Bio-Techne China Co. Ltd Subsidiary · China
    • Cyvek, Inc Subsidiary · Delaware, United States
    • Lunaphore SA Subsidiary · Switzerland
    • Novus Biologicals, LLC Subsidiary · Delaware, United States
    • ProteinSimple Subsidiary · Delaware, United States
    • Research and Diagnostic Systems Inc. (R&D Systems) Subsidiary · Minnesota, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Bio-Techne reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$540.1M6 Jun 30, 2026$531.9M6 Jun 30, 2025+1.5%
Accumulated depreciation$308.3M6 Jun 30, 2026$286.1M6 Jun 30, 2025+7.7%
Property and equipment, net$231.8M6 Jun 30, 2026$245.7M6 Jun 30, 2025−5.6%
Operating-lease assets (leased space)$67.3M6 Jun 30, 2026$73.4M6 Jun 30, 2025−8.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$264.7M6 Jun 30, 2026$162.2M6 Jun 30, 2025+63.2%
Stakes in other companies (equity method)$230.8M6 Jun 30, 2026$236.0M6 Jun 30, 2025−2.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$975.4M6 Jun 30, 2026$980.9M6 Jun 30, 2025−0.6%
Intangible assets, net (excluding goodwill)$303.5M6 Jun 30, 2026$365.6M6 Jun 30, 2025−17.0%
Finite-lived intangibles, gross$895.2M6 Jun 30, 2026$997.7M6 Jun 30, 2025−10.3%
Accumulated amortization$591.7M6 Jun 30, 2026$632.1M6 Jun 30, 2025−6.4%
Finite-lived intangibles, net$303.5M6 Jun 30, 2026$365.6M14 Jun 30, 2025−17.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$195.7M6 Jun 30, 2026$189.4M6 Jun 30, 2025+3.3%
Raw materials$90.3M6 Jun 30, 2026$89.1M6 Jun 30, 2025+1.3%
Finished goods$111.8M6 Jun 30, 2026$106.2M6 Jun 30, 2025+5.3%

Properties, in its own words

The Company owns the facilities that its headquarters and R&D Systems subsidiary occupy in Minneapolis, Minnesota. The Minneapolis facilities are utilized by both the Company’s Protein Sciences and Diagnostics and Spatial Biology segments.

The Minneapolis complex includes approximately 800,000 square feet of space in several adjoining buildings. Bio-Techne uses approximately 710,000 square feet of the complex for administrative, research, manufacturing, shipping and warehousing activities. The Company is currently leasing the remaining space in the complex as retail and office space. The Company also owns a 61,000 square foot facility in Saint Paul, Minnesota that is utilized for additional manufacturing capabilities and activities.

The rest of Item 2

The Company owns a 16,000 square foot facility that its Bio-Techne Europe subsidiary occupies in Abingdon, England. This facility is utilized by the Company’s Protein Sciences and Diagnostics and Spatial Biology segments.

The Company owns a 9,000 square foot facility that its Canada subsidiaries occupy in Toronto, Canada. This facility is utilized by the Company’s Protein Sciences segment.

The Company owns a 53,000 square foot manufacturing facility in Wallingford, Connecticut. This facility is utilized by the Company’s Protein Sciences segment.

The Company leases the following material facilities, which are utilized by both the Company’s Protein Sciences segment and the Diagnostics and Spatial Biology segment. Certain locations are not named because they were not significant individually or in the aggregate as of the date of this report.

Subsidiary · Location · Type · Square Feet

ProteinSimple · San Jose, California · Office/manufacturing/warehouse · 98,000

Novus Biologicals · Centennial, Colorado · Office/warehouse · 74,000

Bionostics · Devens, Massachusetts · Office/manufacturing · 70,000

Cliniqa · San Marcos, California · Office/manufacturing/warehouse · 63,000

PrimeGene · Shanghai, China · Office/manufacturing/lab · 59,000

Advanced Cell Diagnostics · Newark, California · Office/manufacturing/warehouse · 56,000

Asuragen · Austin, Texas · Office/manufacturing/warehouse · 47,000

Tocris · Bristol, United Kingdom · Office/manufacturing/lab/warehouse · 41,000

Bio-Techne China · Shanghai and Beijing, China · Office/warehouse · 34,000

Lunaphore · Tolochenaz, Switzerland · Office/manufacturing/warehouse · 26,000

Bio-Techne Ireland · Dublin, Ireland · Warehouse · 25,000

ProteinSimple Ltd. · Ottawa, Canada · Office/manufacturing/warehouse · 11,000

Bio-Techne France · Rennes, France · Office/warehouse · 11,000

Bio-Techne Germany · Dusseldorf, Germany · Office · 11,000

Item 2 of the 10-K filed Aug 24, 2026.19

The story

The company was founded in 1976 by Roger C. Lucas as Research and Diagnostic Systems, Inc. In 1985, it merged into Techne Corporation and became a public company.

In March 2013, Charles (Chuck) Kummeth was named chief executive officer of the company.

In July 2013, the company acquired Bionostics for $104 million.

In February 2014, the company changed its name to Bio-Techne.

In April 2014, the company agreed to acquire Shanghai PrimeGene Bio-Tech Company (PrimeGene).

In July 2014, the company acquired Novus Biologicals for $60 million.

In August 2014, the company acquired ProteinSimple for $300 million.

In November 2014, the company agreed to acquire CyVek for $60 million plus up to an additional $135 million in earn-out payments.

Read the full text

In June 2015, the company agreed to acquire Cliniqa Corporation.

In March 2016, the company acquired Zephyrus Biosciences.

In July 2016, the company acquired Space Import-Export.

In August 2016, company acquired Advanced Cell Diagnostics for $250 million plus an additional $75 million in possible milestone payments.

In September 2017, the company acquired Trevigen.

In January 2018, the company acquired Atlanta Biologicals.

In June 2018, the company agreed to acquire Quad Technologies.

In August 2018, the company acquired Exosome Diagnostics for $250 million plus up to an additional $325 million in milestone payments.

In June 2019, the company acquired B-Mogen.

In April 2021, the company acquired Asuragen for $215 million plus up to an additional $105 million in milestone payments.

In June 2022, the business announced it would acquire Namocell Inc.

In June 2023, Bio-Techne announced it would acquire Lunaphore Technologies SA, the transaction was completed the following month.

From Wikipedia’s article on Bio-Techne, shared under CC BY-SA 4.0.8

Leadership

Who has led Bio-Techne, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Thomas E. Oland2008–2011
  2. Gregory J. Melsen2012
  3. Charles R. Kummeth2013–2023
  4. Kim Kelderman2024–now

President

  1. Thomas E. Oland2006–2011
  2. Kim Kelderman2018–2019
  3. N. David Eansor2020–2021
  4. William Geist2022–2024
  5. Matthew McManus2024–2026
  6. Steven C. Crouse2026–now

Chief financial officer

  1. Gregory J. Melsen2006–2013
  2. James Hippel2014–now

Chief operating officer

  1. Kim Kelderman2023–2024
19801990200020102020
Board members and other officers (28)

Products and brands

  • protein

Listed on Wikidata.1

Subsidiaries and ownership

Subsidiaries

Subsidiaries (Exhibit 21)

  • Advanced Cell Diagnostics, Inc. California9
  • Asuragen, Inc. Delaware9
  • Bio-Techne China Co. Ltd China9
  • Bio-Techne Ltd. United Kingdom9
  • Cyvek, Inc Delaware9
  • Lunaphore SA Switzerland9
  • Novus Biologicals, LLC Delaware9
  • ProteinSimple Ltd. Canada9
  • Research and Diagnostic Systems Inc. (R&D Systems) Minnesota9

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

  1. Jun 17, 2014Acquired ProteinSimple (United States)1

Former names

  • TECHNE CORP /MN/Sep 20, 1995 to Oct 28, 20147

Timeline

  1. Sep 23, 20268-K Shareholder vote; Regulation FD disclosure58
  2. Sep 14, 20268-K Other events59
  3. Aug 12, 20268-K Results of operations; Other events60
  4. Jun 26, 20268-K Entered a material agreement; Executive or director change61
  5. Jun 25, 20268-K Regulation FD disclosure62
  6. May 6, 20268-K Results of operations; Other events63
  7. Feb 11, 20268-K Executive or director change; Other events64
  8. Feb 4, 20268-K Results of operations; Other events65
  9. Nov 5, 20258-K Results of operations; Shareholder vote; Other events66
  10. Aug 6, 20258-K Results of operations; Other events67
  11. May 7, 20258-K Results of operations; Other events68
  12. May 6, 20258-K Regulation FD disclosure69
  13. Aug 2, 2024New chief executive Kim Kelderman becomes CEO20
  14. Apr 2, 2013New chief executive Charles R. Kummeth becomes CEO21
  15. Dec 4, 2012New chief executive Gregory J. Melsen becomes CEO22
  16. Aug 11, 2008New chief executive Thomas E. Oland becomes CEO23
  17. 1976Founded Founded1

Calendar

Coming up

  1. Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.36 a share, on Nov 5, 2025.70

When it reported results

  1. Aug 12, 2026Reported quarterly or annual results60
  2. May 6, 2026Reported quarterly or annual results63
  3. Feb 4, 2026Reported quarterly or annual results65
  4. Nov 5, 2025Reported quarterly or annual results66
  5. Aug 6, 2025Reported quarterly or annual results67
  6. May 7, 2025Reported quarterly or annual results68
  7. Feb 5, 2025Reported quarterly or annual results71
  8. Oct 30, 2024Reported quarterly or annual results72

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

297 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 39 major events, 178 insider forms, 19 large holders, 41 other. The latest 20:

  1. Sep 30, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  2. Sep 24, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  3. Sep 23, 20268-K EDGAR
  4. Sep 14, 2026DEFA14A EDGAR
  5. Sep 14, 20268-K EDGAR
  6. Sep 9, 2026DEFA14A EDGAR
  7. Sep 2, 2026DEFA14A EDGAR
  8. Aug 25, 2026DEFA14A EDGAR
  9. Aug 24, 202610-K EDGAR
  10. Aug 20, 2026DEFM14A EDGAR
  11. Aug 19, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  12. Aug 19, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  13. Aug 19, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  14. Aug 19, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  15. Aug 19, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  16. Aug 19, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  17. Aug 18, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  18. Aug 18, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  19. Aug 18, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  20. Aug 18, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR

The 297 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

27 open-market trades by officers, directors and large owners since October 2021: 1 buys and 26 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 8, 2026Herr Amy E.DirectorSale6,636$48.28$320.4KForm 4
Feb 17, 2026Herr Amy E.DirectorSale1,976$59.11$116.8KForm 4
Aug 25, 2025Nusse RoelandDirectorSale17,040$56.36$960.4KForm 4
Aug 25, 2025BAUMGARTNER ROBERT VDirectorSale17,040$56.21$957.8KForm 4
Jun 9, 2025Herr Amy E.DirectorSale1,280$49.77$63.7KForm 4
Feb 14, 2025Herr Amy E.DirectorSale1,860$65.96$122.7KForm 4
Jan 27, 2025Kelderman KimChief Executive OfficerSale13,392$77.28$1.0MForm 4
Aug 8, 2024BAUMGARTNER ROBERT VDirectorSale16,000$72.10$1.2MForm 4
May 14, 2024HIGGINS JOHN LDirectorSale4,000$83.84$335.4KForm 4
Mar 7, 2024Nusse RoelandDirectorSale10,400$76.98$800.6KForm 4
Aug 30, 2023Nusse RoelandDirectorSale8,939$80.32$718.0KForm 4
Jul 21, 2023Kummeth Charles R.Chief Executive OfficerSale80,000$88.36$7.1MForm 4
Jun 7, 2023Kummeth Charles R.Chief Executive OfficerSale322$83.00$26.7KForm 4
Dec 8, 2022Furlow Brenda S.SVP - GENERAL COUNSELSale7,450$82.12$611.8KForm 4
Dec 7, 2022Furlow Brenda S.SVP - GENERAL COUNSELSale800$82.01$65.6KForm 4
Aug 11, 2022HIGGINS JOHN LDirectorSale512$385.40$197.3KForm 4
Aug 10, 2022HIGGINS JOHN LDirectorSale1,992$377.10$751.2KForm 4
Jun 8, 2022HIGGINS JOHN LDirectorSale600$366.09$219.7KForm 4
Jun 7, 2022HIGGINS JOHN LDirectorSale1,000$364.31$364.3KForm 4
Jun 7, 2022Kummeth Charles R.Chief Executive OfficerSale5,104$365.00$1.9MForm 4

All 27 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Kim KeldermanPresident and CEO$936.0K$8.2M78
2025James HippelExecutive Vice President and CFO$723.0K$7.0M78
2025William GeistPresident, Protein Sciences$573.2K$3.1M78
2025Matthew McManusPresident, Diagnostics and Spatial Biology$572.0K$2.8M78
2025Shane BohnenSenior Vice President and General Counsel$431.0K$2.0M78
2024Kim KeldermanPresident and CEO$759.5K$6.9M78
2024James HippelExecutive Vice President and CFO$695.2K$5.2M78
2024William GeistPresident, Protein Sciences$551.2K$3.6M78
2024Matthew McManusPresident, Diagnostics and Spatial Biology$253.8K$2.0M78
2024Shane BohnenSenior Vice President and General Counsel$344.8K$1.5M78
2023James HippelExecutive Vice President and CFO$668.4K$3.4M78
2023Kim KeldermanPresident and CEO$589.9K$2.6M78
2023William GeistPresident, Protein Sciences$530.0K$2.3M78
2023Shane BohnenSenior Vice President and General Counsel$331.5K$1.0M78

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.14,025,816$990.9M0.0%+1,761,303
Fmr LLC12,794,784$904.0M0.0%+4,894,856
Vanguard Capital Management LLC10,218,558$721.9M0.0%+38,849
Goldman Sachs Group Inc7,343,324$518.8M0.1%+5,399,790
Hbk Investments L P6,825,000$482.2M6.2%New
Vanguard Portfolio Management LLC6,506,360$459.7M0.0%+26,023
Morgan Stanley6,374,717$450.4M0.0%−2,158,156
State Street Corp5,980,370$422.5M0.0%+111,974
Geode Capital Management, LLC5,351,464$377.5M0.0%+239,044
Invesco Ltd.4,986,424$352.3M0.0%+397,718
Ruane, Cunniff & Goldfarb L.P.3,348,841$236.6M3.7%−43,160
Snyder Capital Management L P3,163,816$223.5M3.9%+1,281,518
Neuberger Berman Group LLC2,844,692$201.0M0.1%−496,145
Massachusetts Financial Services Co /ma/2,746,462$194.0M0.1%−986,786
Mairs & Power Inc2,700,698$190.8M1.8%−49,584
Capital Research Global Investors2,621,890$185.2M0.0%−566,320
UBS Group AG2,478,607$175.1M0.0%−575,736
Dimensional Fund Advisors LP2,253,512$159.2M0.0%+280,376
Whitebox Advisors LLC2,100,001$148.4M7.2%New
Sumitomo Mitsui Trust Group, Inc.2,067,324$146.1M0.1%+13,030
Jpmorgan Chase & Co1,862,805$132.6M0.0%+837,700
Amundi1,827,241$129.1M0.0%+1,754,926
Charles Schwab Investment Management Inc1,622,416$114.6M0.0%−14,146
Maverick Capital Ltd1,535,610$108.5M1.0%−3,204,111
Alliancebernstein L.P.2,002,026$104.6M0.0%−211,171

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

15 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Apr 8, 2026April McClain DelaneyDemocratic, HouseSale$1,001 - $15,000−17.2%Report
Mar 26, 2026April McClain DelaneyDemocratic, HousePartial sale$1,001 - $15,000−18.0%Report
Feb 24, 2026April McClain DelaneyDemocratic, HousePartial sale$1,001 - $15,000−13.6%Report
Jan 28, 2026April McClain DelaneyDemocratic, HousePartial sale$1,001 - $15,000+0.4%Report
Dec 5, 2025April McClain DelaneyDemocratic, HouseBuy$1,001 - $15,000+5.0%Report
Dec 2, 2025April McClain DelaneyDemocratic, HouseBuy$1,001 - $15,000+2.0%Report
Oct 22, 2025April McClain DelaneyDemocratic, HouseBuy$1,001 - $15,000−1.9%Report
Aug 1, 2025April McClain DelaneyDemocratic, HousePartial sale$1,001 - $15,000−8.0%Report
May 26, 2025April McClain DelaneyDemocratic, HousePartial sale$1,001 - $15,000−18.4%Report
Apr 29, 2025April McClain DelaneyDemocratic, HouseBuy$1,001 - $15,000+4.4%Report
Apr 9, 2025April McClain DelaneyDemocratic, HouseBuy$1,001 - $15,000−6.6%Report
Apr 8, 2025Robert P. Bresnahan, Jr.Republican, HouseSale$1,001 - $15,000+6.9%Report
Apr 1, 2025Julie JohnsonDemocratic, HouseSale$1,001 - $15,000+11.1%Report
Feb 25, 2025Robert P. Bresnahan, Jr.Republican, HouseBuy$1,001 - $15,000−17.0%Report
Oct 13, 2020Greg Gianforte, HousePartial sale$1,001 - $15,000+112.8%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Bio-Techne is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBIO-TECHNE Corp2
  • CIK0000842023
  • Employer ID (EIN)41-142740219
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company19
  • Incorporated inMinnesota19
  • Fiscal year endsJune 302
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address614 Mckinley Place Ne, Minneapolis, MN2
  • Mailing address614 Mckinley Place Ne, Minneapolis, MN 554132
  • Phone612-379-88542
  • Shares outstanding156,818,238 shares as of Aug 17, 202619
  • Public float$9.1B as of Dec 31, 202519
  • AuditorKPMG LLP, Minneapolis, Minnesota PCAOB ID 185; it also attests to the company’s internal control over financial reporting19
  • On EDGAR sinceMay 10, 19952
  • Filings1,263 in all: 4 (624), 8-K (181), SC 13G/A (107), 10-Q (94), 10-K (32), DEF 14A (31), 3 (27), 4/A (23)2
    All 30 form types

    DEFA14A (19), SC 13G (19), UPLOAD (18), CORRESP (14), 144 (13), S-8 (10), SD (10), 5 (7), SCHEDULE 13G/A (6), 8-K/A (5), ARS (5), PRE 14A (5), 10-K/A (2), 10-Q/A (2), SCHEDULE 13G (2), DEFM14A (1), NT 10-K (1), NT 10-Q (1), POS AM (1), PREM14A (1), S-3 (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Aug 24, 2026
    Quarterly report (10-Q) May 6, 2026
    Proxy statement (DEF 14A) Sep 19, 2025
    Latest 8-K (8-K) Sep 23, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.01 par valueTECHThe NASDAQ Stock Market LLC

From the cover page of the 10-K filed Aug 24, 2026 (Section 12(b) of the Exchange Act).19

Risk factors and legal proceedings

The risks Bio-Techne names in Item 1A of its 10-K filed Aug 24, 2026: 30 risks under these headings, as written.19

  • Economic and Industry Risks
  • Conditions in the global economy, the particular markets we serve and the financial markets, whether brought about by material global crises or other factors, may adversely affect our business and financial results.
  • International political, compliance and business factors, including the military conflicts and trade tensions, can negatively impact our operations and financial results.
  • The healthcare and life sciences industries that we serve face constant pressures and changes in an effort to reduce healthcare costs or increase their predictability, all of which may adversely affect our business and financial results.
  • Acquisition and Investment Risks
  • Our inability to complete acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price.
  • Our acquisition of businesses, investments, joint ventures and other strategic relationships, if not properly implemented or integrated, could negatively impact our business and financial results.
  • We may be required to record a significant charge to earnings if our goodwill and other amortizable intangible assets or other investments become impaired, which could negatively impact our financial results or stock price.
  • Strategic and Operational Risks
  • Our success will be dependent on recruiting and retaining highly qualified and diverse personnel and creating and maintaining a culture that successfully integrates the employees joining through acquisitions.
  • Our growth depends in part on the timely development and commercialization of new and enhanced products and services that meet our customers’ needs. Our growth can also be negatively impacted if our customers do not grow as anticipated.
  • We face intense competition, and if we are unable to compete effectively, we may experience decreased demand and decreased market share or need to reduce prices to remain competitive.
The other 21 risks
  • A significant disruption in, or breach of security of, our information technology systems or data, or violation of data privacy laws, could result in damage to our reputation, data integrity and/or subject us to costs, fines, or lawsuits under data privacy or other laws or contractual requirements.
  • If we suffer loss to our supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed.
  • The manufacture of many of our products is a complex process, and in many cases subject to complex regulations, and if we directly or indirectly encounter problems manufacturing products, our business and financial results could suffer.
  • If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes in market conditions or customer demand, our business and financial results may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services can cause production interruptions, delays and inefficiencies.
  • The Company relies heavily on internal manufacturing and related operations to produce, package and distribute its products which, if disrupted, could materially impair our business operations. Our business could be adversely affected by disruptions at our sites.
  • Climate change and/or related environmental risks, or legal or regulatory measures to address climate change and/or related environmental risks, may negatively affect us.
  • Defects, unanticipated use of, or inadequate disclosure with respect to our products, or allegations thereof, can adversely affect our business and financial results.
  • Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability.
  • The proposed acquisition of the Company by Merck KGaA, Darmstadt, Germany may disrupt or adversely affect our business, prospects, financial condition and results of operations.
  • We have incurred and expect to continue to incur substantial transaction-related fees and costs in connection with the Merger.
  • The Merger may not be completed within the expected timeframe, or at all, and a significant delay in or the failure to complete the Merger could adversely affect our business and the market price of our common stock.
  • The Merger Agreement contains provisions that could discourage a potential competing acquirer of the Company or could result in a competing proposal being made at a lower price than it otherwise might have been.
  • Intellectual Property Risks
  • We are dependent on maintaining our intellectual property rights. If we are unable to adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights.
  • We may be involved in disputes to determine the scope, coverage and validity of others’ proprietary rights, or to defend against third-party claims of intellectual property infringement, any of which could be time-intensive and costly and may adversely impact our business.
  • Financial and Tax Risks
  • We have entered into and drawn on a revolving credit facility, and we may incur additional debt in the future. The burden of this additional debt could adversely affect us, make us more vulnerable to adverse economic or industry conditions, and prevent us from funding our expansion strategy.
  • Our business and financial results can be adversely affected by foreign currency exchange rates, changes in our tax rates and tax liabilities and assessments (including as a result of changes in tax laws).
  • Dividends on our common stock could be reduced or eliminated in the future.
  • Legal, Regulatory, Compliance and Reputational Risks
  • Significant developments or changes in U.S. laws or policies, including changes in U.S. trade policies and tariffs and the reaction of other countries thereto, can have an adverse effect on our business and financial results.
  • Our business and financial results can be impaired by improper conduct by any of our employees, agents or business partners.
  • Certain of our businesses are subject to extensive regulation by the U.S. FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our business and financial results.
  • Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to the Company’s reputation and have a material adverse effect upon the Company’s business, a risk that has been elevated with recent acquisitions that use protected health information and utilize healthcare providers for laboratory testing services.

Legal proceedings

As of August 24, 2026, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company’s business, results of operations, financial condition or cash flows.

The opening of Item 3, Legal Proceedings.19

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Yahoo FinanceTECH quote
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
    SEC EDGAROther events
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78